Lymphoma, Large B-Cell, Diffuse research hub
6 indexed studies · 4 currently recruiting
- recruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
United States · Belgium · Germany - active not recruitingPHASE1, PHASE2
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing a new cell therapy called Prizlo-Cel for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or is hard to treat. It aims to see if this treatment, which uses your own specially modified cells, is safe and effective.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
This study is testing a new medicine, ALETA-001, for people with certain types of B-cell lymphoma. It's for those who have already had a specific CAR T-cell treatment. The study will look at how safe and effective ALETA-001 is.
United Kingdom - recruitingPHASE1, PHASE2
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
This study looks at a new treatment called MK-1045 for two types of non-Hodgkin lymphoma: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Researchers want to see if MK-1045 is safe and helps shrink the cancer.
Argentina · China · Israel - not yet recruitingPHASE1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This study is testing a new drug, LY4152199, for people with certain types of B-cell lymphoma that have returned or not responded to previous treatments. Researchers want to find the best dose and see how safe and effective it is.
United States · Australia · Canada - active not recruitingPHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
This study is testing a new combination of medicines for older or less fit patients with a type of aggressive B-cell lymphoma who haven't had treatment before. The aim is to see if this new approach, called R-Pola-Glo, is safe and effective.
Austria · Germany